Cyclodextrin based nanoparticles for smart drug delivery in colorectal cancer

Chem Biol Drug Des. 2023 Dec;102(6):1618-1631. doi: 10.1111/cbdd.14344. Epub 2023 Sep 13.

Abstract

The advancement of colorectal cancer (CRC) prevention, detection, and treatment is essential to ensure that survivors live longer and higher-quality lives. The field of cancer detection and therapy has undergone a revolution with the development of nanotechnology for targeted drug delivery. The significant problems with the delivery of cancer drugs are their solubility, stability, and nonspecific distribution. There is a challenge that the acidic and enzymatic environment in the digestive tract will modify or destroy the medication or the active pharmaceutical ingredient. To overcome the problems, nanoparticles have been widely employed during the past several years to increase the specificity, selectivity, and controlled release of drug delivery systems. The site-specific and targeted delivery leads to reduce toxicity and side effects. With respect to the capability and utilization of cyclodextrin-based nanoparticles in different aspects of the tumour microenvironment and gut microbiota, a survey of current research papers was conducted via looking through databases including GoogleScholar, PubMed, Web of Science, and Scopus. This review aims to summarize cutting-edge nanoparticulate-based technologies and therapies for CRC.

Keywords: cancer therapy; colorectal cancer; cyclodextrin; inclusion complexes; nanoparticles.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Colorectal Neoplasms* / drug therapy
  • Cyclodextrins*
  • Drug Delivery Systems / methods
  • Humans
  • Nanoparticles*
  • Pharmaceutical Preparations
  • Tumor Microenvironment

Substances

  • Cyclodextrins
  • Antineoplastic Agents
  • Pharmaceutical Preparations